

Company

Dr. Sulaiman Al Habib
Medical Services
Group
3Q25 Result Review

Rating

Accumulate

Bloomberg Ticker

SULAIMAN AB

Date

27 October 2025

Results


Target Price SAR	321.0
Upside/ Downside	17.1%

Current Market Price (SAR)	274.2
52wk High / Low (SAR)	308.0/227.7
12m Average Vol. (mn)	0.2
Mkt. Cap. (USD/SAR mn)	25,591/95,970
Shares Outstanding (mn)	350.0
Free Float (%)	29.1%
3m ADTV (SAR mn)	46.3
6m ADTV (SAR mn)	48.2
P/E'26e (x)	31.6
EV/EBITDA'26e (x)	25.5
Dividend Yield '26e (%)	2.2%
Price Perf. (1m/3m) (%)	5.1/9.1

Research Department

Email: ubhar-research@u-capital.net

For our
last report

**Revenue growth in 3Q25 comes largely in line with our estimate**

Dr. Sulaiman Al Habib's revenue in 3Q25 jumped 16% YoY, broadly matching our expectations. Both the hospitals and pharmacies segments contributed to revenue growth. The hospital segment benefited from improved occupancy and increased patient volume, as the group added 4 new hospitals since 3Q24.

Increased fixed operating costs constrain net profit growth

Despite strong revenue growth, net profit rose only 1% YoY in 3Q25, in line with our estimate. An increase in fixed operating costs from the opening of new hospitals currently in ramp-up curbed net profit growth.

U Capital View

We expect Dr. Sulaiman's profitability to start improving next year onwards as the newly added hospitals move towards their optimum utilization levels. Hence, we maintain our Accumulate rating on the stock. The company's BoD has proposed a DPS of SAR 1.21 for 3Q25 (3Q24: SAR 1.20), indicating a payout ratio of ~70%, in line with its historical trend.

Financial Summary

SAR mn	3Q24	4Q24	1Q25	2Q25	3Q25	3Q25e	YoY	QoQ	Var.	9M24	9M25	YoY
P&L												
Revenue	2,977	3,129	3,158	3,384	3,463	3,638	16%	2%	-5%	8,072	10,005	24%
Gross profit	992	997	1,028	1,066	1,050	1,163	6%	-2%	-10%	2,747	3,144	14%
Operating profit	624	624	626	645	666	693	7%	3%	-4%	1,732	1,937	12%
Net profit	596	614	557	591	602	620	1%	2%	-3%	1,702	1,750	3%
BS												
Sh. Equity	6,991	7,175	7,291	7,495	7,684		10%	3%		6,991	7,684	10%
Ratios												
GPM	33.3%	31.9%	32.6%	31.5%	30.3%	32.0%				34.0%	31.4%	
OPM	21.0%	19.9%	19.8%	19.1%	19.2%	19.1%				21.5%	19.4%	
NPM	20.0%	19.6%	17.6%	17.5%	17.4%	17.0%				21.1%	17.5%	
EPS, SAR	1.70	1.75	1.59	1.69	1.72	1.77				4.86	5.00	
RoE (TTM)					31.9%							
TTM P/E (x)					40.6							
Current P/B (x)					12.5							

Source: Financials, Tadawul, Bloomberg, U Capital Research



Investment Research

Ubhar-Research@u-capital.net

Head of Research

Tahir Abbas

+968 2494 9036 | tahir@u-capital.net

Research Team

Ahlam Al Harthi

+968 2494 9024 | ahlam.harthi@u-capital.net

Sandesh Shetty

+968 2494 9059 | sandesh@u-capital.net

Amira Al Alawi

+968 2494 9012 | amira.alalawi@u-capital.net

Dua Al Mawali

+968 2494 9021 | dua@u-capital.net

Head of Brokerage

Talal Al Balushi

+968 2494 9051 | talal@u-capital.net

Visit us at

www.u-capital.net

Disclaimer

Recommendation

BUY	ACCUMULATE	HOLD	REDUCE	SELL
Greater than 20%	Between +10% and +20%	Between +10% and -10%	Between -10% and -20%	Lower than -20%

Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net

PO Box 1137, PC 111, Sultanate of Oman

Tel: +968 2494 9036 | **Fax:** +968 2494 9099 | **Email:** research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.